Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gadobenate dimeglumine

Drug Profile

Gadobenate dimeglumine

Alternative Names: B-19036; B-19036/7; E 7155; Gadobenic acid; Gd-BOPTA/Dimeg; MultiHance

Latest Information Update: 06 Feb 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bracco Diagnostics
  • Class Diagnostic agents; Gadolinium-containing contrast agents; Hexosamines; Organometallic compounds; Small molecules; Sugar alcohols
  • Mechanism of Action Magnetic resonance imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Arterial occlusive disorders; CNS disorders

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 30 Jan 2018 The label for gadobenate dimeglumine contains a black box warning for nephrogenic systemic fibrosis
  • 30 Jan 2018 The US Food and Drug Administration approves gadobenate dimeglumine for CNS disorders (Diagnosis, In neonates, In infants) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top